Document Detail


Pharmacoepidemiology and rheumatic diseases: 2001-2002.
MedLine Citation:
PMID:  12598798     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pharmacoepidemiology is the branch of epidemiology that focuses on medications and their outcomes, including both adverse events and intended consequences. Such studies have become more prominent in rheumatology as the number of new medications has grown and prescribing databases have become more available. In the past year, the potential cardiovascular complications associated with selective COX-2 inhibitors have become an important concern. A number of pooled analyses suggest the possibility of an increased risk of acute myocardial infarction, and studies of naproxen have found a possible protective effect. Accumulating evidence supports the contention that early initiation of disease modifying antirheumatid drug therapy improves outcomes of patients with rheumatoid arthritis. Open-label extensions of biologic therapies found continued benefits extending several years with the TNF-alpha antagonists, but concerns have arisen regarding tuberculosis and central nervous system demyelination with these agents. Data continue to be published quantifying the risk of osteoporosis associated with glucocorticoids, and the association between biphosphonate therapy and upper gastrointestinal events appears to be less of a concern that originally described.
Authors:
Daniel H Solomon; Jerry Avorn
Related Documents :
1561998 - Milwaukee prehospital chest pain project--phase i: feasibility and accuracy of prehospi...
3983908 - Treatment with stanozolol before thrombolysis in patients with arterial occlusions.
2525898 - Nonemergent cardiac catheterization and risk-stratified revascularization following thr...
617018 - The natural history of coronary artery disease: an update on surgical and medical manag...
9811408 - Are efforts at expanding the donor pool misdirected?
7449658 - In-vitro toxicity of acetone using coronary perfusion in isolated rabbit heart.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Current opinion in rheumatology     Volume:  15     ISSN:  1040-8711     ISO Abbreviation:  Curr Opin Rheumatol     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-02-24     Completed Date:  2003-04-11     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9000851     Medline TA:  Curr Opin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  122-6     Citation Subset:  IM    
Affiliation:
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. dhsolomon@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use
Antirheumatic Agents / adverse effects*,  therapeutic use*
Cyclooxygenase Inhibitors / adverse effects,  therapeutic use
Female
Glucocorticoids / adverse effects,  therapeutic use
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use
Male
Pharmacoepidemiology*
Rheumatic Diseases / diagnosis,  drug therapy*,  epidemiology
Risk Assessment
Sensitivity and Specificity
Grant Support
ID/Acronym/Agency:
K23 AR48616/AR/NIAMS NIH HHS; R01 DA15507/DA/NIDA NIH HHS; R55 AR48264/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antirheumatic Agents; 0/Cyclooxygenase Inhibitors; 0/Glucocorticoids; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic epidemiology: disease susceptibility and severity.
Next Document:  Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literatu...